Clinical bottom line
Digital therapeutics (DTx) for smoking cessation in primary care show promising feasibility and acceptability, with some evidence supporting improved quit rates when combined with standard care. Mobile applications and web-based interventions can enhance patient engagement, provide behavioral support, and facilitate monitoring. However, evidence from large, high-quality randomized controlled trials remains limited, and integration into routine primary care workflows is variable. Digital tools may serve as valuable adjuncts to pharmacotherapy and counseling, particularly for motivated patients with access to technology (Wongvibulsin et al., 2021; Bankston et al., 2016).
What the evidence shows
Wongvibulsin et al. (2021) systematically reviewed digital health interventions across cardiovascular rehabilitation, including smoking cessation components, finding that digital platforms can improve adherence and support behavior change. Although not exclusively focused on smoking cessation, their findings highlight the potential of digital tools to augment traditional interventions.
Bankston et al. (2016) specifically assessed the feasibility of a mobile application for smoking cessation in a primary care population, reporting good user engagement and satisfaction. Preliminary data suggested increased quit attempts, though the study was limited by small sample size and lack of a control group.
Corsello et al. (2026) emphasize the importance of tailored, age-appropriate digital interventions for adolescents, noting that digital tools can address barriers to access and stigma associated with smoking cessation.
Coteur et al. (2026) review patient values and preferences, highlighting that individuals with severe mental illness appreciate digital interventions for their convenience and privacy, though they may require additional support to maximize benefit.
Earlier foundational evidence by Sheikh et al. (2000) underscores the importance of behavioral support combined with pharmacotherapy, a principle that digital therapeutics aim to replicate and enhance through scalable platforms.
Caveats and uncertainty
Most digital therapeutic studies for smoking cessation are pilot or feasibility trials with limited sample sizes and short follow-up durations.
Heterogeneity in digital intervention design, intensity, and user engagement complicates comparisons.
Digital literacy and access disparities may limit applicability in some primary care populations.
Evidence on long-term abstinence and cost-effectiveness of digital therapeutics remains insufficient.
Integration into primary care workflows and clinician acceptance vary widely.
How this may change practice
Primary care providers may consider recommending evidence-based digital therapeutics as adjuncts to counseling and pharmacotherapy, especially for patients motivated to use technology.
Digital tools can facilitate remote monitoring, personalized feedback, and ongoing support, potentially improving quit rates.
Training and workflow adjustments may be needed to integrate digital therapeutics effectively.
Future research and guideline updates may clarify optimal patient selection and intervention components.
Clinicians should remain aware of evolving digital health options and patient preferences to enhance smoking cessation efforts.